NBGI Private Equity today announces the acquisition of Stiplastics for an undisclosed sum.

Stiplastics is a specialist manufacturer of injection-molded plastic dosing, packaging solutions, and medical devices for the pharmaceutical industry including pillboxes, medication blister packs, and "tamper proof" systems. The company employs around 70 staff and operates production facilities in Beauvoir en Royans, France.

Stiplastics is a market leader in OTC products, including the Spoonbox measuring spoon, containers for transporting healthcare products, measuring cups and an extensive range of Pilbox pill dispensers. Its clients include major groups in the pharmaceutical, cosmetics and food manufacturing sectors such as Novartis, Sanofi Aventis and Danone.

NBGI will support the Stiplastics' existing management team, which has ambitious plans to almost double revenues in the next five years, from €12.5 million in 2012 to €23 million in 2017. The strategy is to expand Stiplastics' range of products and to leverage its reputation and relationships around the world. Over 50% of the company's sales are generated outside of France and its local partners have already expressed strong interest in distributing the new products that are currently under development.

Stiplastics is the third investment made from NBGI Private Equity France Fund I.